Table 3

Univariate and multivariate cox regression analyses for overall survival in patients with nasopharyngeal carcinoma in the validation cohort

VariablesUnivariate analysisMultivariate analysis
HR (95% CI)P valuesHR (95% CI)P values
Sex
 Female versus male0.53 (0.29 to 1.00)0.049*0.76 (0.40 to 1.45)0.408†
Age
 ≥50 versus <501.77 (1.05 to 2.99)0.034*1.96 (0.95 to 4.52)0.056†
BMI
 >25 versus ≤250.72 (0.39 to 1.33)0.294
T stage0.004*0.002*†
 T1Ref.Ref.
 T24.93 (1.15 to 21.08)0.032*5.03 (1.17 to 21.76)0.030*
 T35.41 (1.28 to 22.91)0.022*5.37 (1.26 to 22.91)0.023*
 T410.24 (2.39 to 43.84)<0.001*11.48 (2.65 to 49.68)0.001*
N stage0.010*0.010*†
 N0Ref.Ref.
 N12.90 (0.97 to 8.62)0.0563.08 (1.03 to 9.23)0.044*
 N23.28 (1.16 to 9.31)0.026*4.20 (1.46 to 12.07)0.008*
 N36.38 (2.06 to 19.71)0.001*6.64 (2.11 to 20.91)0.001*
Chemotherapy
 Yes versus no1.05 (0.60 to 1.82)0.868
IMRT
 Yes versus no0.92 (0.56 to 1.53)0.756
SIRI
 >0.84 versus ≤0.843.10 (1.69 to 5.68)<0.001*2.91 (1.56 to 5.41)0.001*†
NLR
 >1.85 versus ≤1.852.82 (1.44 to 5.52)0.003*2.99 (1.51 to 5.95)0.002*‡
PLR
 >112 versus ≤1121.57 (1.03 to 2.70)0.042*1.74 (1.01 to 3.03)0.048*§
MLR
 >0.29 versus ≤0.291.77 (1.08 to 2.90)0.024*1.54 (0.93 to 2.54)0.093¶
  • *represents a statistically significant difference.

  • †The variables (sex, age, T stage, N stage and SIRI) were tested in a multivariate analysis.

  • ‡The variables (sex, age, T stage, N stage and NLR) were tested in a multivariate analysis.

  • §The variables (sex, age, T stage, N stage and PLR) were tested in a multivariate analysis.

  • ¶The variables (sex, age, T stage, N stage and MLR) were tested in a multivariate analysis.

  • BMI, body mass index;  IMRT, intensity-modulated radiotherapy; MLR, monocyte lymphocyte ratio; NLR, neutrophil lymphocyte ratio; PLR, platelet lymphocyte ratio; Ref, reference;  SIRI, Systemic Inflammation Response Index.